A Phase 1 interventional study of MLN1117 and TAK-659 in Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).
The drug being tested in this study is called MLN1117. MLN1117 is being tested to treat people who have locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This study will look at the dose-limiting toxicity and response to treatment in participants who take MLN1117 in combination with TAK-659, alisertib, paclitaxel, or docetaxel.
The study will enroll 32 participants in the dose escalation phase (Part 1) and 118 participants in the dose expansion phase (Part 2). Participants will be assigned to 1 of the 7 treatment groups:
In Part 1, the dose of MLN1117 will be increased step by step. All participants will be asked to take tablets of MLN1117 for 3 days on and 4 days off per week in 28-day treatment cycles or 21-day treatment cycles when given in combination with the other companion drugs.
This multi-center trial will be conducted in Spain and United States. The overall time to participate in this study is 10 months for Part 1 and 24 months for Part 2. Participants will make multiple visits to the clinic, and be contacted by telephone, e-mail or mail every 12 weeks for up to 6 months or 1 year after the last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1 and Part 2
Has adequate organ and hematologic function as evidenced by the following laboratory values within 14 days before enrollment:
Female participants who:
Male participants, even if surgically sterilized (ie, status postvasectomy), who:
Part 1 only
Part 2 only
Exclusion Criteria:
Part 1 and Part 2
Has comorbidities, such as uncontrolled pulmonary disease, known impaired cardiac function or clinically significant cardiac disease, active central nervous system disease, or any other condition that could compromise the participant's participation in the study.
Part 2 only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117 · Drug: Alisertib
MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117 · Drug: Alisertib
MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117 · Drug: Paclitaxel
MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117 · Drug: Paclitaxel
MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 \[NCT02000934\]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
Drug: MLN1117 · Drug: TAK-659 · Drug: Docetaxel
MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117 · Drug: Docetaxel
MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
Drug: MLN1117
MLN1117 Tablets
Also known as: TAK-117
TAK-659 Tablets
Alisertib Tablets
Also known as: MLN8237
Paclitaxel intravenous infusion
Docetaxel intravenous infusion
Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1
Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of following considered related to any of treatment by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; ≥ Grade 3 neutropenia with coincident fever or infection; Grade 4 thrombocytopenia for \>7 days; Grade 3 thrombocytopenia with clinically significant bleeding; Platelet count \<10,000/mm\^3 at any time; Delay in initiation of subsequent therapy cycle by \>7 days due to treatment-related toxicity; ≥Grade 3 nonhematological toxicity except Grade 3 arthralgia/myalgia, fatigue that lasts \<1 month, diarrhea, fasting hyperglycemia lasting ≤14 days, rash lasting ≤7 days and any other Grade 3 nonhematological toxicity that could be safely, reliably controlled to ≤Grade 1 with appropriate treatment; ≥ Grade 2 nonhematologic toxicities that are considered by investigator to be related to study drugs and dose-limiting.
Time frame: Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)
Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. There are 5 grades of the CTCAE; "grade" refers to severity. Grade 5 is the most severe, grade 1 is the least severe. As per version 4.0 of the CTCAE, Grade 3 = AE with severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 = AE with life-threatening consequences; urgent intervention indicated and Grade 5 = Death related to AE.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Number of Participants With at Least 1 Dose Modification Due to AE in Part 1
A decision regarding which study drug requires dose modification is dependent upon the toxicity, its onset, and time course. The causal relationship of each AE should will be assessed in relation to MLN1117 and to the combination agent in each cohort so that dose modifications can be made accordingly. Intrapatient dose reductions of MLN1117 are not permitted during Part 1 Cycle 1 unless the participant experiences a DLT attributed to MLN1117. Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels. When a dose reduction of MLN1117 occurs, the MLN1117 dose will be reduced to the next lower dose that has been established as a safe dose during dose escalation (Part 1).
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Overall Response Rate in Part 2
Overall response is defined as complete response (CR) plus partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) version 1.1 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Number of Participants With at Least 1 TEAE and Serious TEAE in Part 1 and 2
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Number of Participants With Dose Delays, Dose Reductions, and Dose Interruptions Due To AE in Part 1 and 2
Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Progression-Free Survival (PFS) Based on RECIST Criteria V 1.1 Assessment in Part 2
PFS is defined as the time from the date of randomization to the date of first documentation of Progressive disease (PD) or death due to any cause, whichever occurs first. PD is defined as an increase of \>=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest).
Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Percentage of Participants With Disease Control Based on RECIST Criteria V 1.1 Assessment in Part 2
Disease control rate is defined as the percentage of participants with complete response (CR) + Partial response (PR) + stable disease (SD) according to RECIST version 1.1 criteria. CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as not qualifying for CR, PR, or PD.
Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Duration of Response (DOR) Based on RECIST Criteria V 1.1 Assessment in Part 2
DOR is defined as the time from the date of first documentation of a response to the date of first documentation of PD according to RECIST version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Time to Disease Progression (TTP) Based on RECIST Criteria V 1.1 Assessment in Part 2
TTP is defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)
Overall Survival (OS) Based on RECIST Criteria V 1.1 Assessment
OS is defined as the time from the date of randomization to the date of death.
Time frame: From randomization up to end of Part 2, then every 12 weeks until participant death or until 1 year after the last dose of study drug, whichever occurs first (up to 336 days)
Plasma Concentration of MLN1117-1003
Time frame: MLN1117 300 mg + Alisertib arms: Cycle 1 Day 3; MLN1117 300 mg + Paclitaxel arms and MLN1117 200 mg + Docetaxel arms: Cycle 1 Day 2; MLN1117 300 mg + TAK-659 arm: Cycle 1 Days 1 and 17
Participants took part in the study at 3 investigative sites in Spain and the United States from 15 October 2015 to 18 January 2017.
| Milestone | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Part 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 6 | 3 | 6 | 7 | 2 | 4 | 0 |
| Completed | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Not completed | 4 | 6 | 2 | 5 | 7 | 1 | 3 | 0 |
| Withdrew: Death | 2 | 4 | 2 | 2 | 2 | 1 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of following considered related to any of treatment by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; ≥ Grade 3 neutropenia with coincident fever or infection; Grade 4 thrombocytopenia for \>7 days; Grade 3 thrombocytopenia with clinically significant bleeding; Platelet count \<10,000/mm\^3 at any time; Delay in initiation of subsequent therapy cycle by \>7 days due to treatment-related toxicity; ≥Grade 3 nonhematological toxicity except Grade 3 arthralgia/myalgia, fatigue that lasts \<1 month, diarrhea, fasting hyperglycemia lasting ≤14 days, rash lasting ≤7 days and any other Grade 3 nonhematological toxicity that could be safely, reliably controlled to ≤Grade 1 with appropriate treatment; ≥ Grade 2 nonhematologic toxicities that are considered by investigator to be related to study drugs and dose-limiting.
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1 | 4 | 6 | 3 | 6 | 7 | 2 | 4 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. There are 5 grades of the CTCAE; "grade" refers to severity. Grade 5 is the most severe, grade 1 is the least severe. As per version 4.0 of the CTCAE, Grade 3 = AE with severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 = AE with life-threatening consequences; urgent intervention indicated and Grade 5 = Death related to AE.
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1 | 4 | 4 | 2 | 2 | 6 | 2 | 4 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1 | 2 | 3 | 1 | 2 | 5 | 2 | 4 |
A decision regarding which study drug requires dose modification is dependent upon the toxicity, its onset, and time course. The causal relationship of each AE should will be assessed in relation to MLN1117 and to the combination agent in each cohort so that dose modifications can be made accordingly. Intrapatient dose reductions of MLN1117 are not permitted during Part 1 Cycle 1 unless the participant experiences a DLT attributed to MLN1117. Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels. When a dose reduction of MLN1117 occurs, the MLN1117 dose will be reduced to the next lower dose that has been established as a safe dose during dose escalation (Part 1).
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Number of Participants With at Least 1 Dose Modification Due to AE in Part 1 | 0 | 1 | 1 | 0 | 4 | 0 | 1 |
Overall response is defined as complete response (CR) plus partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) version 1.1 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
No measurements were reported for this outcome.
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Part 2 |
|---|---|---|---|---|---|---|---|---|
| AE | 4 | 6 | 3 | 6 | 7 | 2 | 4 | — |
| SAE | 2 | 3 | 1 | 2 | 5 | 2 | 4 | — |
Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels.
| Participants | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Part 2 |
|---|---|---|---|---|---|---|---|---|
| Dose delay due to AE | 0 | 0 | 0 | 0 | 1 | 0 | 0 | — |
| Dose reduction due to AE | 0 | 1 | 1 | 0 | 4 | 0 | 1 | — |
| Dose interruption due to AE | 0 | 0 | 1 | 0 | 0 | 0 | 0 | — |
PFS is defined as the time from the date of randomization to the date of first documentation of Progressive disease (PD) or death due to any cause, whichever occurs first. PD is defined as an increase of \>=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest).
No measurements were reported for this outcome.
Disease control rate is defined as the percentage of participants with complete response (CR) + Partial response (PR) + stable disease (SD) according to RECIST version 1.1 criteria. CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as not qualifying for CR, PR, or PD.
No measurements were reported for this outcome.
DOR is defined as the time from the date of first documentation of a response to the date of first documentation of PD according to RECIST version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
No measurements were reported for this outcome.
TTP is defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
No measurements were reported for this outcome.
OS is defined as the time from the date of randomization to the date of death.
No measurements were reported for this outcome.
| ng/mL | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| Day 1: Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 0.00 ± 0.000 | NA ± NA | NA ± NA |
| Day 1: 0.5 Hour Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 675.04 ± 816.641 | NA ± NA | NA ± NA |
| Day 1: 1 Hour Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2171.00 ± 1840.041 | NA ± NA | NA ± NA |
| Day 1: 2 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 3054.14 ± 1811.084 | NA ± NA | NA ± NA |
| Day 1: 3 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 3315.29 ± 1521.130 | NA ± NA | NA ± NA |
| Day 1: 4 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 3164.71 ± 1522.096 | NA ± NA | NA ± NA |
| Day 1: 6 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2726.71 ± 1259.976 | NA ± NA | NA ± NA |
| Day 1: 8 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2466.29 ± 1112.350 | NA ± NA | NA ± NA |
| Day 1: 24 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1045.17 ± 642.781 | NA ± NA | NA ± NA |
| Day 2: Predose | NA ± NA | NA ± NA | 0.00 ± 0.000 | 0.00 ± 0.000 | NA ± NA | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Day 2: 0.5 Hour Postdose | NA ± NA | NA ± NA | 1762.00 ± 1295.728 | 1701.17 ± 1407.015 | NA ± NA | 3240.00 ± 1230.366 | 1333.05 ± 1970.336 |
| Day 2: 1 Hour Postdose | NA ± NA | NA ± NA | 3840.00 ± 747.195 | 3261.83 ± 2879.952 | NA ± NA | 3165.00 ± 1859.691 | 1554.00 ± 2042.092 |
| Day 2: 2 Hours Postdose | NA ± NA | NA ± NA | 4066.67 ± 322.542 | 3934.00 ± 3419.860 | NA ± NA | 4615.00 ± 4433.560 | 1456.23 ± 1577.178 |
| Day 2: 3 Hours Postdose | NA ± NA | NA ± NA | 3653.33 ± 325.628 | 3753.50 ± 3324.071 | NA ± NA | 4355.00 ± 4362.849 | 1598.75 ± 1269.397 |
| Day 2: 4 Hours Postdose | NA ± NA | NA ± NA | 3206.67 ± 256.970 | 3994.67 ± 3191.500 | NA ± NA | 3725.00 ± 3542.605 | 1475.75 ± 1062.242 |
| Day 2: 6 Hours Postdose | NA ± NA | NA ± NA | 2720.00 ± 10.000 | 4311.67 ± 2752.595 | NA ± NA | 3085.00 ± 2920.351 | 1417.75 ± 907.208 |
| Day 2: 8 Hours Postdose | NA ± NA | NA ± NA | 2536.67 ± 87.369 | 3246.00 ± 2026.285 | NA ± NA | 3025.00 ± 2807.214 | 1443.25 ± 992.241 |
| Day 2: 24 Hours Postdose | NA ± NA | NA ± NA | 592.67 ± 38.527 | 1279.83 ± 1238.550 | NA ± NA | 717.00 ± 668.923 | 420.80 ± 477.731 |
| Day 3: Predose | 2177.50 ± 1453.717 | 3178.82 ± 2696.065 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 0.5 Hour Postdose | 3225.00 ± 693.229 | 4554.80 ± 3431.547 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 1 Hour Postdose | 5010.00 ± 1376.590 | 5070.60 ± 3278.807 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 2 Hours Postdose | 5007.50 ± 1192.347 | 6235.80 ± 4139.804 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 3 Hours Postdose | 4815.00 ± 810.535 | 5650.00 ± 3995.103 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 4 Hours Postdose | 4797.50 ± 1240.225 | 4719.20 ± 3100.983 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 6 Hours Postdose | 4777.50 ± 1753.024 | 4501.80 ± 2904.730 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 8 Hours Postdose | 4320.00 ± 1862.078 | 4354.80 ± 2836.444 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 3: 24 Hours Postdose | 2217.33 ± 1604.245 | 2357.42 ± 1806.031 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 17: Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 978.33 ± 1519.070 | NA ± NA | NA ± NA |
| Day 17: 0.5 Hour Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2893.67 ± 1738.859 | NA ± NA | NA ± NA |
| Day 17: 1 Hour Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 5596.67 ± 387.599 | NA ± NA | NA ± NA |
| Day 17: 2 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 5583.33 ± 1146.575 | NA ± NA | NA ± NA |
| Day 17: 3 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 5116.67 ± 1608.426 | NA ± NA | NA ± NA |
| Day 17: 4 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 5066.67 ± 2009.784 | NA ± NA | NA ± NA |
| Day 17: 6 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 4293.33 ± 1654.398 | NA ± NA | NA ± NA |
| Day 17: 8 Hours Postdose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 4330.00 ± 2606.971 | NA ± NA | NA ± NA |
Collected over From first dose of study drug through 30 days after the last dose of study drug. Related SAEs could be reported at any time after discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MLN1117 300 mg + Alisertib | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| MLN1117 600 mg + Alisertib | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| MLN1117 300 mg + Paclitaxel | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| MLN1117 600 mg + Paclitaxel | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| MLN1117 300 mg + TAK-659 | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| MLN1117 200 mg + Docetaxel | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| MLN1117 300 mg + Docetaxel | 2/4 (50%) | 4/4 (100%) | 4/4 (100%) |
| Event | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/4 | 0/6 | 0/3 | 0/6 | 1/7 | 0/2 | 2/4 |
| PneumoniaInfections and infestations | 0/4 | 0/6 | 0/3 | 0/6 | 0/7 | 1/2 | 0/4 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/6 | 0/3 | 0/6 | 0/7 | 1/2 | 2/4 |
| Liver function test increasedInvestigations | 0/4 | 0/6 | 0/3 | 0/6 | 0/7 | 1/2 | 0/4 |
| Neutrophil count decreasedInvestigations | 0/4 | 0/6 | 0/3 | 0/6 | 0/7 | 1/2 | 0/4 |
| Rectal haemorrhageGastrointestinal disorders | 0/4 | 0/6 | 1/3 | 0/6 | 0/7 | 0/2 | 0/4 |
| Neuroendocrine carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/6 | 1/3 | 0/6 | 0/7 | 0/2 | 0/4 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/6 | 0/3 | 0/6 | 1/7 | 0/2 | 1/4 |
| Small intestinal obstructionGastrointestinal disorders | 0/4 | 0/6 | 0/3 | 0/6 | 0/7 | 0/2 | 1/4 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/4 | 0/6 | 0/3 | 0/6 | 0/7 | 0/2 | 0/4 |
| Event | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/4 | 4/6 | 1/3 | 2/6 | 0/7 | 1/2 | 4/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/4 | 1/6 | 1/3 | 0/6 | 1/7 | 2/2 | 0/4 |
| FatigueGeneral disorders | 3/4 | 3/6 | 1/3 | 0/6 | 1/7 | 1/2 | 2/4 |
| NauseaGastrointestinal disorders | 0/4 | 2/6 | 2/3 | 2/6 | 4/7 | 1/2 | 1/4 |
| Abdominal painGastrointestinal disorders | 1/4 | 4/6 | 1/3 | 2/6 | 0/7 | 0/2 | 0/4 |
| ConstipationGastrointestinal disorders | 2/4 | 0/6 | 2/3 | 0/6 | 1/7 | 0/2 | 1/4 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 4/6 | 0/3 | 1/6 | 2/7 | 1/2 | 1/4 |
| Oedema peripheralGeneral disorders | 1/4 | 1/6 | 2/3 | 0/6 | 1/7 | 0/2 | 0/4 |
| Night sweatsSkin and subcutaneous tissue disorders | 0/4 | 1/6 | 2/3 | 1/6 | 2/7 | 0/2 | 0/4 |
| VomitingGastrointestinal disorders | 2/4 | 2/6 | 1/3 | 3/6 | 4/7 | 0/2 | 0/4 |
Safety population is defined as all participants who received at least 1 dose of any study drug. Participants are analyzed according to the treatment actually received.
| Age, Continuous(years) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 61.5 ± 7.94 | 59.0 ± 4.86 | 65.3 ± 13.28 | 62.2 ± 11.82 | 62.3 ± 9.16 | 65.5 ± 4.95 | 62.3 ± 9.95 | 62.0 ± 8.61 |
| Sex: Female, Male(Participants) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 3 | 5 | 7 | 2 | 2 | 25 |
| Male | 1 | 3 | 0 | 1 | 0 | 0 | 2 | 7 |
| Race/Ethnicity, Customized(participants) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Not Hispanic or Latino | 4 | 6 | 3 | 5 | 6 | 2 | 3 | 29 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| White | 4 | 4 | 2 | 6 | 6 | 1 | 4 | 27 |
| Black or African American | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 4 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 4 | 5 | 3 | 3 | 6 | 2 | 4 | 27 |
| Spain | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 5 |
| Height(cm) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 162.90 ± 14.178 | 165.50 ± 10.145 | 159.80 ± 4.513 | 162.83 ± 15.108 | 158.76 ± 6.662 | 154.95 ± 7.142 | 166.25 ± 16.674 | 162.07 ± 10.939 |
| Weight(kg) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 77.75 ± 15.314 | 71.63 ± 19.725 | 74.07 ± 12.756 | 82.38 ± 25.474 | 65.53 ± 13.046 | 75.45 ± 43.911 | 68.28 ± 21.403 | 73.13 ± 19.400 |
| Body Surface Area(m^2) | MLN1117 300 mg + Alisertib | MLN1117 600 mg + Alisertib | MLN1117 300 mg + Paclitaxel | MLN1117 600 mg + Paclitaxel | MLN1117 300 mg + TAK-659 | MLN1117 200 mg + Docetaxel | MLN1117 300 mg + Docetaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 1.825 ± 0.2814 | 1.802 ± 0.2863 | 1.809 ± 0.1638 | 1.917 ± 0.3496 | 1.694 ± 0.1790 | 1.768 ± 0.5769 | 1.767 ± 0.3734 | 1.796 ± 0.2796 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Feb 2017, 16 months.
Results were first posted in Sep 2019, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Serabelisib
Millennium Pharmaceuticals, Inc. →